Amgen has revealed a development program for a biosimilar rival to Keytruda (pembrolizumab), as it revealed first-quarter results for 2024 that saw its biosimilars business grow sales by 12%.
“We announced today the development of a biosimilar to Keytruda,” said Amgen chairman and CEO Bob Bradway, “as we look to build upon the